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ABSTRACT
Angiogenin is progressively upregulated in prostate cancer, in particular in androgen-independent diseases. The objective of this project is to explore the role angiogenin plays in the development of androgen-independent disease. In this reporting period, we have demonstrated that nuclear translocation of angiogenin is specific for prostate cancer cells and does not occur in normal prostate epithelial cells. Angiogenin is translocated to the nucleus of androgen-dependent cells (LNCaP) only when the cells are stimulated with androgen (DHT). But angiogenin is constitutively translocated to the nucleus of androgen-independent cells (PC-3, PC-3M, DU145). Angiogenin is required for DHT to stimulate rRNA transcription and cell proliferation of androgen-dependent cells. Overexpression of angiogenin enables androgen-independent growth of otherwise androgen-dependent prostate cancer cells in vitro and in vivo. Finally, we have shown that angiogenin binds to the promoter region of rDNA in vivo and stimulates rRNA transcription.
Introduction
The goal of this study is to understand the molecular mechanism of angiogenin-mediated growth of androgen-independent growth of prostate cancer. This goal will be achieved by two specific aims. Specific aim 1 is to demonstrate the role of angiogenin in prostate cancer by characterizing the growth of angiogenin over-expressing LNCaP cells in castrated athymic mice and angiogenin under-expressing PC-3 cells in non-castrated mice. Specific aim 2 is to elucidate the mechanism by which angiogenin stimulates rRNA transcription. These two specific aims will be accomplished in 6 tasks.
In the previous year report, we had made substantial progress to task 1 (Months 1-9) and had completed task 2 (Months 10-18). In the current year report, we have completed task 1 and task 3 (Months 19-22) and have initiated task 4 (Months 23-27).
Body
Task 1: Task 1 is to characterize the growth of angiogenin over-expressing LNCaP cell in castrated athymic mice. In the last report we had shown that (1) Exogenous angiogenin stimulates proliferation of LNCaP cells but not that of PC-3, PC-3M, and DU145 cells, (2) . Over-expression of angiogenin in LNCaP cells promotes androgen-independent proliferation in vitro. Now we have demonstrated that angiogenin overexpression enables LNCaP cell growth in castrated SCID mice (Fig. 1c ).
Over-expression of angiogenin in LNCaP cells promotes androgen-independent proliferation and tumorigenesis
The angiogenin expression vector pCI-ANG that carries human angiogenin cDNA under the CMV promoter and the control vector pCI-Neo were transfected into LNCaP cells and stable transfectants expressing 6.6-times higher angiogenin were selected (Fig. 1a) . Angiogenin overexpression stimulated LNCaP proliferation in the absence of androgen (Fig. 1b) . To determine whether angiogenin over-expression promotes androgen-independent proliferation in vivo, these transfectants were inoculated into castrated SCID mice. Both the vector and angiogenin transfectants established tumors in uncastrated mice. However, only 1 of the 8 mice had palpable tumors in castrated mice inoculated with vector transfectants, whereas 7 of the 8 castrated mice developed tumors when inoculated with angiogenin transfectants (Fig. 1c) . These results indicate that angiogenin over-expression enables LNCaP cells to proliferate in the absence of androgen both in vitro and in vivo. We have also demonstrated that angiogenin stimulates rRNA transcription and is required for DHT-mediated rRNA transcription and cell proliferation.
Angiogenin binds to the promoter region of ribosomal DNA (rDNA) and stimulates rRNA transcription
Our previous in vitro study has identified three angiogenin binding DNA elements (ABE) in the promoter region of rDNA 1 . ABE has been shown to have angiogenin-dependent promoter activity in a luciferase reporter assay 1 . However, it remained unknown whether angiogenin binds to ABE in vivo and whether this binding is responsible for rRNA transcription. We therefore studied in vivo binding of ANG to the promoter region of rDNA by chromatin immunoprecipitation (ChIP). Fig. 2 shows that angiogenin binds to ABE1, ABE2, and to the upstream control element (UCE) where the essential transcription factor UCE binding factor (UBF) binds. Fig. 2f is a schematic illustration of angiogenin binding to the promoter region of rDNA. rRNA transcription in LNCaP cells is stimulated by exogenous angiogenin and inhibited by anti-angiogenin IgG 26-2F as shown by Northern blotting analysis (Fig. 2g) . Moreover, 26-2F inhibited androgen dihydrotestosterone (DHT)-induced rRNA transcription, indicating that DHT-induced rRNA transcription is mediated by angiogenin.
Angiogenin is constitutively translocated to the nucleus of androgen-independent prostate cancer cells
These results, together with the results in the previous year report, suggest that nuclear angiogenin undergoes nuclear translocation where it binds to the promoter region of ribosomal DNA, stimulates rRNA transcription, and thereby drives cell proliferation. Nuclear translocation is thus a prerequisite for the nuclear function of angiogenin. We therefore examined nuclear translocation of ANG in androgen-dependent and androgen-independent prostate cancer cells in the presence or absence of androgen. No nuclear angiogenin was detectable by immunofluorescence in RWPE-1 normal prostate epithelial cells either in the absence or presence of DHT (Fig. 3a,b) . LNCaP cells express a promiscuous gain-of-function mutant androgen receptor (AR) 2 and are able to respond to the physiological level of androgens. Nuclear angiogenin was detected in LNCaP cells only when the cells were stimulated with DHT (Fig. 1c,d ). PC-3, PC-3M, and DU145 cells are deficient in AR and grow in the absence of androgens 3 . Angiogenin is constitutively translocated to the nucleoli of these cells both in the absence and in the presence of DHT (Fig. 3e-j) . Western blotting analysis with an anti-human angiogenin polyclonal antibody R113 (Fig. 3k,l) showed that in PC-3, PC-3M and DU145 cells, comparable amounts of angiogenin protein were detected when equal amounts of nuclear protein, extracted from cells cultured in the absence (Fig. 3k) or presence (Fig. 3l) of androgen, were applied. However, in LNCaP cells, Angiogenin was detectable only in the nuclear protein extracted from DHT-stimulated cells (Fig. 3l) . No angiogenin protein was detected by Western blotting in the nuclear protein extracted from RWPE-1 cells cultured under both conditions. Thus, nuclear translocation of angiogenin is specific for prostate cancer cells and does not occur in normal prostate epithelial cells. Furthermore, there is a correlation between nuclear translocation of angiogenin and the growth status of the cancer cells.
Task4: Task 4 is to determine the effect of angiogenin on ribosomal promoter occupancy by SL1, an essential transcription factor for rRNA. We have initiated this task and have prepared AAV-angiogenin siRNA. This siRNA will be used to knockdown angiogenin expression in LNCaP cells. Together with the addition of exogenous angiogenin and anti-angiogenin antibody, we will be able to manipulate angiogenin levels in LNCaP cells and determine the resultant changes in SL1 binding to rDNA promoter by ChIP assays.
Key Research Accomplishment
• Demonstrated that angiogenin overexpression enable LNCaP cells to establish tumor in castrated mice. Provided in vivo evidence that angiogenin plays a role in the transition of prostate cancer to androgen independence.
• Demonstrated that angiogenin binds to the promoter region of ribosomal DNA.
Determined the in vivo binding sites and proposed a mechanism by which angiogenin stimulates rRNA transcription.
• Demonstrated that angiogenin is required for androgen to induce rRNA transcription in androgen-dependent prostate cancer cells.
• Determined the differential nuclear translocation pattern of angiogenin in normal prostate epithelial cells, androgen-dependent and androgen-independent prostate cancer cells. 
Conclusion
In this reporting period, we have shown that angiogenin binds to ABE in the promoter region of rDNA and stimulates rRNA transcription. We have also shown that angiogenin is constitutively in the nucleus of androgen-independent cells, suggest that upregulation and constitutive nuclear translocation of angiogenin will result in a constant supply of rRNA, which may contribute to the development of androgen independency through the so-called "bypass" AR pathway 4 . We have shown that rRNA transcription in LNCaP cells in response to DHT stimulation is inhibited by anti-angiogenin IgG, indicating that AR-stimulated rRNA transcription is mediated by angiogenin. Consistently, angiogenin has been found to undergo nuclear translocation in LNCaP cells upon DHT stimulation. Moreover, anti-angiogenin IgG abolishes DHT-induced LNCaP cell proliferation in a dose-dependent manner. These results suggest that angiogenin is required for DHT to stimulate cell proliferation. Finally, exogenous angiogenin can compensate for the loss of androgen-AR signaling axis and ectopic expression of angiogenin enables LNCaP cells to proliferate in the absence of androgen and to establish tumors in castrated mice. Together, these results clearly demonstrate that angiogenin plays an essential role in AR-dependent cell proliferation and that upregulation of angiogenin may contribute to the development of androgen independence.
The research is on track. No changes or modifications are foreseen for the next 12 months.
